Which 14 of the 19 Peptides Are Becoming Legal Again?

In late 2023, the Food and Drug Administration (FDA) removed 19 peptides from their FDA Category 1 list to FDA Category 2. This was because the FDA identified significant, unresolved patient safety risks, making the 19 peptides ineligible for routine compounding by traditional, 503A pharmacies. However, at the time, some clinicians and compounding pharmacies argued the agency overstepped.

On February 27, 2026, while doing an interview on The Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. (RFK Jr.) discussed the FDA’s current restrictions on peptides, stating his intention was to make peptides more accessible. 

RFK Jr. indicated he is working to overturn the 2023 FDA decision that banned compounding pharmacies from producing certain peptides listed in Category 2. He stated he’d like to move 14 of the 19 peptides currently listed under FDA Category 2 back to FDA Category 1, which would allow them to be compounded by traditional, 503A pharmacies. 

What’s important to note is that this reclassification has not yet happened.

As of this writing:

• The FDA has not published formal reclassification guidance.

• Discussions continue for the 14 peptides under Category 2

• Category 2 peptides cannot be used in compounding unless the FDA authorizes their use through rulemaking 

• The governing regulatory framework remains unchanged.

You can review the FDA’s compounding framework here.

You can monitor formal federal regulatory updates via the Federal Register here.

This article provides clarity on:

• Which peptides are under discussion

• What Category 2 status means today

• What peptides can currently be prescribed under 503A compounding

• And how healthcare organizations should prepare if reclassification occurs

Which 14 Peptides Are Coming Back?

An official FDA list has not been published yet, but based on industry analysts and regulatory experts, these peptides are considered to be the most likely to return to legal compounding. It’s important to clarify that this is not an official list, as none has been released. It reflects industry-informed predictions only.

The peptides frequently being referenced in reclassification conversations include:

• AOD-9604

• BPC-157

• Emideltide (DSIP — Delta Sleep-Inducing Peptide)

• Epitalon (Epithalamin)

• GHK-Cu (Copper Peptide)

• Kisspeptin-10

• KPV

• MOTS-C

• Semax

• Selank

• TB-500 (Thymosin Beta-4 Fragment)

• Thymosin Alpha-1

Despite public discussion, these peptides remain categorized as Category 2 under current FDA policy and are not eligible for patient-specific 503A compounding.

What The FDA Category 1 vs Category 2 Status Means Today

Under the FDA’s interim bulk substances framework for 503A pharmacies:

• Category 1: Bulk Drug Substances under evaluation with sufficient supporting safety information; may be compounded while under review by the FDA.

• Category 2: Bulk Drug Substances that identify as presenting significant safety risks; cannot be used in compounding unless the FDA authorizes their use through rulemaking.

• Category 3: Bulk Drug Substances lacking sufficient documentation or evidence for the FDA to evaluate them and cannot be compounded as active ingredients.

Category 2 substances are specifically identified as raising significant safety concerns. Prescribing and compounding Category 2 peptides places prescribers and 503A compounding pharmacies at risk of federal or state enforcement.

 Until final FDA rulemaking  moves these peptides out of Category 2 and into Category 1 their regulatory status remains unchanged.

Category 1 Bulk Substances

Peptides listed as Category 1 may be compounded by 503A pharmacies with a valid,patient-specific prescription while under FDA review.

The 14 peptides discussed above are not currently on that eligible list.

Reclassification vs FDA Approval

It is critical to understand that reclassification is not the same as FDA approval.

• Reclassification to Category 1 would allow 503A pharmacies to compound a substance while it remains under FDA evaluation.

• Reclassification does not mean the peptide has been approved by the FDA as a finished drug product.

• FDA approval requires formal clinical trials, safety and efficacy review, labeling approval, and manufacturing validation under a New Drug Application (NDA) or Biologics License Application (BLA).

• Category 1 status simply indicates the substance may be compounded under interim policy — it does not establish proven safety, efficacy, or standardized dosing.

• Compounded medications are not evaluated or approved by the FDA for safety, efficacy or quality

Healthcare leaders are closely monitoring the peptide  regulatory approval pathways.

​​What Healthcare Leaders Need to Know Now

Current Regulatory Reality

• The 14 peptides discussed publicly remain Category 2 substances.

• The FDA has not issued formal reclassification guidance.

• Category 2 peptides cannot be used in compounding unless the FDA authorizes their use through rulemaking 

• The regulatory framework governing bulk substances is unchanged.

• Healthcare organizations are still monitoring changes in FDA guidance.

What Reclassification May Mean for Healthcare Leaders

If these peptides formally move to Category 1, leaders might expect both opportunity and complexity across five major areas:

1. Expanded Clinical Pathways

Category 1 status would provide clearer regulatory footing and could enable structured, compliant prescribing pathways.

For organizations with scalable clinical oversight infrastructure, this could unlock:

• Program expansion

• Standardized protocols

• Increased patient demand

• Greater legitimacy in the market

However, readiness will determine who capitalizes on the opportunity.

2. Supply Chain & Pharmacy Partnerships

One of the most significant impacts would occur at the pharmacy level.

Potential effects include:

• Shifts in pharmacy participation

• Ingredient sourcing constraints

• Production capacity bottlenecks

• Quality and sterility verification demands

Organizations relying on fragmented or loosely governed pharmacy networks may face disruption. Leaders should evaluate:

• Diversified sourcing strategies

• Depth of pharmacy compliance controls

• Contractual flexibility

• Real-time regulatory monitoring

3. Margin & Cost Structure Impact

Reclassification could affect:

• Cost of goods

• Ingredient pricing

• Pharmacy compounding fees

• Shipping and cold-chain logistics

• Reimbursement assumptions

As supply stabilizes or demand increases, pricing volatility is likely. Leaders should proactively model:

• Gross margin sensitivity

• Program pricing flexibility

• Inventory risk exposure

• Cash flow implications

5. Patient Demand & Market Dynamics

If regulatory positioning becomes clearer, demand may increase rapidly.

But transitional friction — including pharmacy bottlenecks — could create short-term access constraints.

Organizations with integrated operations, structured intake, and scalable fulfillment systems will be positioned to meet demand.

Others may experience:

• Backlogs

• Patient dissatisfaction

• Refund risk

• Reputational damage

How OpenLoop Health Approaches Peptide Therapy

Peptide therapy is one of the treatment modalities offered within OpenLoop Health–supported clinical programs. When prescribed, it is delivered within a structured, compliance-driven framework designed to prioritize patient safety, regulatory alignment, and clinical oversight.

Our approach includes:

• Licensed clinician oversight. All prescribing decisions are made by appropriately licensed healthcare providers based on individualized medical evaluation, clinical judgment, and documented medical necessity.

• Regulatory-aligned pharmacy partnerships. We work with compliant state-licensed 503A compounding pharmacies operating in accordance with applicable federal and state regulations.

• Lot-level third-party testing. Our partner pharmacies must source their active pharmaceutical ingredients (APIs) from FDA registered manufacturers. The API must be accompanied by a valid Certificate of Analysis which verifies the APIs quality and compliance with regulatory standards and conducts routine and rigorous third-party quality testing to check for potency, sterility, quality and contamination to ensure patient safety in compliance with state and United States Pharmacopeia standards.

No Reclassification Has Happened, Yet.

The 14 peptides remain Category 2 substances today and they are not currently eligible for routine 503A compounding despite certain public commentary.

However, if reclassification does occur, it may create both opportunity and operational strain across clinical programs, pharmacy networks, compliance infrastructure, and financial models.

Healthcare leaders who treat this moment as a strategic planning window will be best positioned to adapt if the status changes. 

*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.